QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: From Safety Concern to Formal EU Referral

Test your understanding of the concepts covered by How an EMA Safety Referral Starts: From Safety Concern to Formal EU Procedure.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is reconstructing the chronology of a safety issue important during a referral?

It demonstrates that the company predicted the final regulatory outcome. It shows what was known, assessed and decided at each stage and supports traceability of the pharmacovigilance system's reasoning. It allows the MAH to exclude later evidence from consideration. It replaces the need for current case and epidemiological analyses.

Question 2 of 10 Why is simple counting of adverse-event reports insufficient for deciding whether a safety concern warrants escalation?

Because all adverse-event reports are excluded from signal management until confirmed by clinical trials. Because report counts cannot be interpreted without considering evidence quality, exposure, alternative explanations and the clinical context. Because only reports originating from healthcare professionals can support regulatory action. Because a high number of reports automatically requires an Article 107i procedure.

Question 3 of 10 Which internal response structure is most likely to reduce inconsistent positions across departments during a referral?

Allow each department to submit its own interpretation independently. Use one controlled question set, one evidence inventory, clear ownership and documented decision-making. Limit review to the regulatory department to preserve speed. Permit changes to the scientific position without recording the rationale.

Question 4 of 10 Which recordkeeping practice best supports inspection and regulatory defensibility during a referral?

Manage the procedure primarily through informal email exchanges. Maintain a controlled record of the legal basis, scope, questions, evidence, decisions, communications and submissions. Retain only the final response because earlier assessments are superseded. Store each function's records separately without reconciliation.

Question 5 of 10 Which statement best describes the QPPV's role in relation to a major safety referral?

The QPPV must personally make every legal decision initiating the referral. The QPPV should ensure that the referral remains connected to an adequate, governed and auditable pharmacovigilance system. The QPPV's role ends once the formal notification is received. The QPPV should replace all regulatory and medical functions during the referral.

Question 6 of 10 What is the principal regulatory effect of the formal initiating notification?

It confirms that causality has been established. It establishes the legal and scientific frame, including the concern, questions, scope and regulatory action to be considered. It replaces the need for an MAH evidence package. It constitutes the final European Commission decision.

Question 7 of 10 Which sequence best represents the conceptual progression described in the article?

Formal referral, signal detection, routine monitoring, final decision, legal-route selection. New information, pharmacovigilance evaluation, potential signal, regulatory assessment, consideration of Union action, legal-route selection and formal initiation. Final regulatory action, PRAC assessment, signal validation, new information and routine monitoring. Product withdrawal, referral publication, case collection and signal detection.

Question 8 of 10 Which statement correctly describes the relationship between seriousness and urgency?

Any serious safety concern automatically requires Article 107i. Urgency and seriousness are identical regulatory concepts. A concern may be scientifically serious without meeting the statutory criteria for Article 107i, while urgency is determined by the applicable legal circumstances. An urgent procedure does not require scientific assessment.

Question 9 of 10 Before selecting Article 20, Article 31 or Article 107i, what should be determined first?

Whether the company prefers a PRAC or CHMP assessment. Whether the concern requires Union-level action at all and what regulatory problem must be addressed. Whether the MAH has already prepared a variation. Whether the safety concern has been published in the medical literature.

Question 10 of 10 Why must an MAH map the EU authorisation landscape for an active substance when considering escalation?

Because only products owned by the MAH can ever be assessed. Because the authorisation routes and products potentially affected influence the available Union legal pathways and formal scope. Because the authorisation route determines whether an adverse event is medically serious. Because centrally authorised products are not subject to pharmacovigilance.

Knowledge Assessment: From Safety Concern to Formal EU Referral

Cookie Settings